Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
The world of biotech stocks is notoriously difficult to predict. History is littered with companies that appeared destined for superstar status only to crash and burn....
NEW YORK, Sept. 14, 2022 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB) between January 17, ...
NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB) between January 17, 2018 and June...
Enochian Biosciences Inc (NASDAQ: ENOB) shares are trading lower Wednesday after Hindenburg Research issued a bearish report on the company. Last week, federal prosecutors announced the arrest of t...
Enochian Bioscience is in the green today following the shocking arrest of the company founder earlier this week. ENOB stock closed up 20%....
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bri...
The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) increased by over 3% pre-market today. This is why it happened....
Company encouraged by clear path to IND in near-term following its review of the FDA's Center for Biologics Evaluation and Research written comments Company encouraged by clear path to IND in near-ter...
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced t...
